Described herein are diagnostic methods for selecting patients diagnosed with diffuse large B-cell lymphoma (DLBCL) for treatment with an inhibitor of Brutons tyrosine kinase (BTK) based on the level of expression the biomarkers CCL3 and/or CCL4. Also provided are methods for identifying DLBCL patients likely to respond to treatment with a BTK inhibitor and for evaluating treatment of DLBCL with a BTK inhibitor. Methods of treating a patient also are provided. Also provided are compositions, combinations, and kits.
